Expression of tumor necrosis factor alpha-induced protein 3 mRNA in peripheral blood mononuclear cells negatively correlates with disease severity in psoriasis vulgaris

Clinical and Vaccine Immunology

Volumn 19, Issue 12, 2012, Pages 1938-1942

  Jiang, Xuebing ^a   Tian, Hongqing ^b,e   Fan, Yuchen ^c   Chen, Jie ^a   Song, Yonghong ^d   Wang, Shurong ^d   Zhu, Faliang ^a   Guo, Chun ^a   Zhang, Lining ^a   Shi, Yongyu ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

^d Shandong Blood Center   (China)

^e SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADOLESCENT; ADULT; ARTICLE; BODY SURFACE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC AREA AND SEVERITY INDEX; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SCORING SYSTEM; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3 GENE; UPREGULATION;

ADOLESCENT; ADULT; AGED; CHILD; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PSORIASIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84870476159     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00500-12     Document Type: Article

References (28)

1. Abrams JR, et al. 2000. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192:681-694.
2. Adrianto I, et al. 2011. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat. Genet. 43:253-258.
3. Anderson KS, et al. 2010. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br. J. Dermatol. 163:1085-1089.
4. Arican O, Aral M, Sasmaz S, Ciragil P. 2005. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005:273-279. (Pubitemid 41577417)
5. Boonyasrisawat W, et al. 2007. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes 56:499-505.
6. Chanudet E, et al. 2010. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 24:483-487.
7. Coornaert B, Carpentier I, Beyaert R. 2009. A20: central gatekeeper in inflammation and immunity. J. Biol. Chem. 284:8217-8221.
8. Düwel M, et al. 2009. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J. Immunol. 182:7718-7728.
9. Elder JT. 2009. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun. 10:201-209.
10. Frenzel LP, et al. 2011. Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus. Int. J. Cancer 128:2495-2500.
11. Henseler T, Schmitt-Rau K. 2008. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int. J. Dermatol. 47:1019-1023.
12. Kanelleas A, et al. 2011. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin. Exp. Dermatol. 36:845-850.
13. Kingeter LM, Paul S, Maynard SK, Cartwright NG, Schaefer BC. 2010. Cutting edge: TCR ligation triggers digital activation of NF-kappaB. J. Immunol. 185:4520-4524.
14. Krikos A, Laherty CD, Dixit VM. 1992. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J. Biol. Chem. 267:17971-17976.
15. Lodolce JP, et al. 2010. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J. Immunol. 184:7001-7009.
16. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. 1997. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J. Dermatol. Sci. 14:145-153. (Pubitemid 27107150)
17. Nair RP, et al. 2009. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41:199-204.
18. Nograles KE, Davidovici B, Krueger JG. 2010. New insights in the immunologic basis of psoriasis. Semin. Cutan. Med. Surg. 29:3-9.
19. Reich K. 2012. The concept of psoriasis as a systemic inflammation: implications for disease management. J. Eur. Acad. Dermatol. Venereol. 26(Suppl 2):3-11.
20. Song QH, et al. 2012. An association study of single nucleotide polymorphisms of the FOXP3 intron-1 and the risk of psoriasis vulgaris. Indian J. Biochem. Biophys. 49:25-35.
21. Song XT, et al. 2008. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med. 14:258-265.
22. Sun H, et al. 2008. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 133:415-426. (Pubitemid 351608694)
23. Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. 2010. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin. Exp. Dermatol. 35:645-649.
24. Vereecke L, Beyaert R, van Loo G. 2011. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem. Soc. Trans. 39:1086-1091.
25. Vereecke L, Beyaert R, van Loo G. 2009. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 30:383-391.
26. Vereecke L, et al. 2010. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp. Med. 207:1513-1523.
27. Verstrepen L, et al. 2010. Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem. Pharmacol. 80:2009-2020.
28. Xie S, et al. 2010. IL-17 activates the canonical NF-kappaB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of regulators of G-protein signaling 16. J. Immunol. 184:2289-2296.